COSCIENS Biopharma Inc. (CSCIF) stock
Close on Oct 19, 2026Market cap $24.10MP/E –Yield –
COSCIENS Biopharma Inc. saw revenue fall 11.6% to $7.89M over the twelve months to Mar 31, 2026. Free cash flow was -$8.86M. At the latest close the market valued the company at $24.10M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Mar 31, 2026
Valuation
- Market cap
- $24.10M
- P/E ratio
- –
- Price to sales
- 3.06
- Price to book
- 1.57
- Dividend yield
- –
- Free cash flow yield
- -36.77%
Fundamentals
- Revenue
- $7.89M
- EPS, diluted
- -$3.27
- Free cash flow
- -$8.86M
- Book value per share
- $4.12
- Diluted shares
- 4M
Trading
- Previous close
- $6.49
- Open
- $6.49
- Day's range
- $6.49 – $6.49
- Volume
- 0
- Average volume (20 days)
- 1,185
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | CSCIF | S&P 500 | Difference | CSCIF per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +21.3% | +0.6% | +20.7 pts | ||
| 3 months | +12.9% | +3.4% | +9.5 pts | ||
| Year to date | +215.0% | +13.3% | +201.8 pts | ||
| 1 year | +147.7% | +16.6% | +131.1 pts | ||
| 3 years | -3.4% | +86.4% | −89.8 pts | -1.2% | +23.1% |
| 5 years | -89.5% | +81.9% | −171.4 pts | -36.3% | +12.7% |
| 10 years | -98.6% | +318.9% | −417.5 pts | -34.8% | +15.4% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
EPS, diluted
Free cash flow
Press releases
Releases COSCIENS Biopharma filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About COSCIENS Biopharma
Perfumes, Cosmetics & Other Toilet Preparations
COSCIENS Biopharma Inc. is a biopharmaceutical enterprise focused on the extraction, production, and commercialization of active ingredients from natural sources. Its operations encompass biopharmaceutical development as well as active ingredients for the nutraceuticals market, notably oat-based pipeline products such as oat-beta glucan and avenanthramides, along with yeast-derived beta glucan. The organization also advances and scales proprietary Pressurized Gas eXpanded technology. Its customer base includes commercial distributors, healthcare partners, and biopharmaceutical clients across global regions.
Company profile, executives and historyCOSCIENS Biopharma stock: common questions
What is COSCIENS Biopharma's stock price?
CSCIF closed at $6.49 on Oct 19, 2026, up 0.00% on the day.
What is COSCIENS Biopharma's market cap?
COSCIENS Biopharma was worth $24.10M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is CSCIF's P/E ratio?
COSCIENS Biopharma lost money over fiscal 2025 (diluted EPS -$3.27), so it has no meaningful P/E ratio.
How much revenue does COSCIENS Biopharma make?
COSCIENS Biopharma reported revenue of $7.89M for the twelve months to Mar 31, 2026, down 11.6% from a year earlier.
Does COSCIENS Biopharma pay a dividend?
No. COSCIENS Biopharma has not paid a cash dividend over the last twelve months.
How has CSCIF stock performed over the past year?
Including dividends, CSCIF returned +147.7% over the past year, against +16.6% for the S&P 500.
Who are COSCIENS Biopharma's competitors?
Companies most similar to COSCIENS Biopharma by business, industry and size include UG, DQWS, YCBD, SLSN, AXIL.
See a number that looks wrong?